Moderna's mRNA bird flu vaccine trial is close to getting U.S. government fundingByBruce GilUpdatedMay 30, 2024
Pfizer plans to cut costs by $1.5 billion as demand for COVID vaccine dwindlesByBruce GilPublishedMay 22, 2024
Novavax stock skyrockets 120% on $1.2 billion vaccine deal with SanofiByRocio FabbroUpdatedMay 10, 2024
Wegovy sales surge, COVID vax sales sink, and 'junk' patents: Pharma news roundupByBruce GilPublishedMay 3, 2024
The Dow closes 300 points higher and the S&P 500 looks to break a losing streak as investors wait for AppleByVinamrata ChaturvediUpdatedMay 2, 2024
Moderna stock surges 15% after it beat earnings expectations despite plummeting COVID vaccine salesByRocio FabbroUpdatedMay 2, 2024
Nvidia CEO Jensen Huang says companies will 'still want human' workers as AI growsByBritney NguyenUpdatedApril 29, 2024
Ozempic hits booze sales, Moderna likes AI, and Biogen's blockbuster drug: Pharma news roundupByBruce GilPublishedApril 26, 2024
Meta's AI annoys, Microsoft and Amazon under scrutiny, banks go all-in: AI news roundupByBritney NguyenPublishedApril 26, 2024
Moderna's CEO wants employees to use ChatGPT at least 20 times a dayByBritney NguyenUpdatedApril 25, 2024
The top companies for training workers to use AI — including Amazon and GMByLaura BrattonPublishedApril 16, 2024
Activist investor blasts Novavax for not using mRNA fears to boost COVID-19 vaccine salesByBruce GilUpdatedApril 15, 2024
Moderna's new cancer vax, AstraZeneca CEO's big pay, and record-high drug shortages: Pharma news round upByBruce GilPublishedApril 12, 2024
Moderna paused its plans for a facility in Kenya because COVID-19 vaccine demand has plummetedByBruce GilPublishedApril 11, 2024
